Otolith Labs welcomes Dan Wagner as CCO and Raphael Michel as Board Member

WASHINGTON – Otolith Labs, a pioneering medical device company, is proud to announce the addition of Dan Wagner as Chief Commercial Officer (CCO) and Raphael Michel as an independent member of its Board. Bringing a combined expertise of over 40 years, both Dan and Raphael are set to enhance Otolith Labs’ journey in the medical and consumer device market.

Dan Wagner takes the helm of Otolith’s market strategy, focusing on building comprehensive infrastructure for market access, medical affairs, sales operations, and marketing. Otolith Labs is at the forefront of developing a groundbreaking head-worn wearable device aimed at alleviating vertigo symptoms linked to vestibular migraines. This innovative headband employs precise mechanical stimulation to the vestibular system, offering a new hope for chronic vertigo sufferers.

“Having advised Otolith for over five years, Dan’s full-time commitment is a significant milestone for us. His extensive background in medical device commercialization is invaluable to our strategic growth and market introduction.”

Sam Owen, CEO and Founder of Otolith Labs

Dan Wagner’s remarkable career spans over 17 years in the medical device and biotechnology sectors, with a global footprint across more than 60 countries and various healthcare specialties. His leadership roles at notable companies like Olympus Corporation and Spark Biomedical have been instrumental in achieving corporate growth and operational excellence.

Raphael Michel, joining as an independent Board member, brings a wealth of over 20 years in technology and business innovation. His journey from the foundational team member at Vessix Vascular to leadership roles at Google’s X Labs illustrates a commitment to transforming healthcare through innovation. Raphael’s experience is expected to play a crucial role in guiding Otolith towards a successful market launch.

“Raphael’s long-standing advisory role since 2016 has been pivotal. His expertise and leadership are invaluable assets as we progress towards commercializing our technology.”

Sam Owen, CEO and Founder of Otolith Labs

Otolith Labs is at the cutting edge of developing prescription medical devices aimed at treating vestibular disorders, affecting millions nationwide. With its patented technology, recognized by the FDA as a Breakthrough Device for chronic vertigo treatment, Otolith is revolutionizing the approach to managing vestibular disorder symptoms through clinically evaluated, vibration-based therapy.